Lin Yang
Associate Director, Discovery Alloy Therapeutics
Seminars
Thursday 25th June 2026
Accelerating T Cell Receptor–Mimic (TCRm) Antibody Discovery & Anti-CD3 Optimization through Mammalian Cell–Based Directed Evolution & AI/ML-Guided Digital Design
9:30 am
- TCRm antibodies enable next-generation T cell engagers to target intracellular antigens through peptide–MHC (pMHC) complexes inaccessible to conventional antibodies
- Developing effective T cell engagers requires balancing high pMHC specificity, strong affinity for low-abundance targets, and optimized anti-CD3 activity for potency and safety
- Alloy combines mammalian cell–based directed evolution with AI/ML-guided design to accelerate development of highly selective, potent, and developable T cell engagers
